BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 22, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» Ribox’s RXRG-001 cleared to enter clinic for radiation-induced xerostomia and hyposalivation
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Ear, nose & throat
Ribox’s RXRG-001 cleared to enter clinic for radiation-induced xerostomia and hyposalivation
Oct. 28, 2024
No Comments
Ribox Therapeutics Ltd. has obtained IND clearance from the FDA for the company’s circular RNA therapy, RXRG-001.
BioWorld Science
Regulatory
Cancer
Ear, nose and throat
FDA
IND
